The International Prognostic Index was developed prior to the development of rituximab. The revised IPI is a rescaling based on current outcomes.
Parameters:
(1) age of the patient in years
(2) serum LDH in U/L relative to the upper limit of the normal reference range (ULN)
(3) ECOG performance status
(4) Ann Arbor stage
(5) extranodal sites
Parameter
Finding
Points
age of the patient
<= 60 years
0
> 60 years
1
serum LDH
<= ULN
> ULN
ECOG performance
0 or 1
2 to 4
Ann Arbor stage
I or II
III or IV
extranodal sites
<= 1
>= 2
total score =
= SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 5
Revised IPI Score
Risk Group
4 Year Overall Survival
very good
94%
1 or 2
good
79%
3 to 5
poor
55%
Original IPI Score
low
82%
2
low-intermediate
81%
3
high-intermediate
49%
4 or 5
high
59%
To read more or access our algorithms and calculators, please log in or register.
Purpose: To evaluate a patient with diffuse large B-cell lymphoma (DLBCL) using the Revised International Prognostic Index (R-IPI)
Specialty: Hematology Oncology
Objective: severity, prognosis, stage
ICD-10: C83.3,
